Health Catalyst, Inc.

NASDAQ:HCAT

Medical - Healthcare Information Services

Healthcare
$1.29 -1.98%

-$0.04 today

Market cap
$98.24M
Beta
1.66
P/E (TTM)
-0.5
EPS (TTM)
-$3.65
52W Low $0.96High $4.13

Volume 0.27M

Average 1.24M

HCAT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Health Catalyst, Inc.NASDAQ: HCAT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 33.4%

Gross margin was 33.4% in Q1 FY2026, down 12.2 pp from a year earlier. On a trailing-twelve-month basis it was 46.0%, up 0.7 pp year over year. Over 3 fiscal years it narrowed by 14.7 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
33.4%-19.3 pp QoQ
Last fiscal yearDec 2025
33.5%-12.5 pp YoY
LTMMar 2026
46.0%+0.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-12.2 pp——
1 year-12.5 pp——
3 years-14.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
33.5%
Year-over-year change
-12.5pp

Gross Margin vs competitors

How HCAT compares with its peers on the latest reported figures

  • HCAT's LTM Mar 2026 gross margin of 46.0% is the 9th highest of the 11 companies compared; the peer median is 95.9%.
  • Its year-over-year change of +0.7 pp is the 5th highest of 9, against a peer median of +1.9 pp.
  • Over three fiscal years its change of -14.7 pp compares with a peer median of +3.0 pp.
HCAT Competitors Peer median
Gross Margin for HCAT and competitors
Company Period LTM level YoY 3-year change
TNYATenaya Therapeutics, Inc.LTM Mar 2026144.9% ——
PYXSPyxis Oncology, Inc.LTM Mar 202699.8% ——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202699.3% +6.7 pp+8.5 pp
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
HSDTSolana CompanyLTM Mar 202694.2% +127.8 pp+50.5 pp
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
SNWVSANUWAVE Health, Inc.LTM Mar 202675.7% -0.9 pp+3.0 pp
HCATHealth Catalyst, Inc.LTM Mar 202646.0% +0.7 pp-14.7 pp
OMOutset Medical, Inc.LTM Mar 202640.6% +4.7 pp+23.7 pp
NNOXNano-X Imaging Ltd.LTM Dec 2025-98.2% -3.3 pp-18.0 pp
Peer median (excluding HCAT) 95.9%+1.9 pp+3.0 pp

Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue241.93M276.24M295.94M306.58M311.14M
Cost of Revenue124.35M143.05M164.11M165.81M207M
Gross Profit117.57M133.19M131.83M140.78M104.13M
Gross Margin48.6%48.2%44.5%45.9%33.5%
Research & Development62.73M75.68M72.63M57.95M49.77M
Selling, General & Admin160.96M149.22M143.88M111.2M102.04M
Operating Expenses261.22M273.19M258.73M210.59M140.24M
Depreciation & Amortization41.11M51.53M42.22M41.43M50.5M
EBITDA(101.68M)(82.92M)(68.28M)(10.65M)(110.35M)
EBITDA Margin-42.0%-30.0%-23.1%-3.5%-35.5%
Operating Income(143.65M)(140.01M)(126.9M)(69.81M)(36.1M)
Operating Margin-59.4%-50.7%-42.9%-22.8%-11.6%
Interest Income831K5.69M16.39M17.98M7.54M
Interest Expense17.31M7.24M7.29M17.09M16.4M
Other Income / Expenses(16.46M)(1.68M)9.11M637K(141.15M)
Income Before Tax(160.11M)(141.68M)(117.79M)(69.17M)(177.26M)
Pre-Tax Margin-66.2%-51.3%-39.8%-22.6%-57.0%
Income Tax Expense(6.9M)(4.28M)356K333K716K
Net Income(153.21M)(137.4M)(118.15M)(69.5M)(177.97M)
Net Margin-63.3%-49.7%-39.9%-22.7%-57.2%
EPS (Basic)(3.23)(2.56)(2.09)(1.15)(2.55)
EPS (Diluted)(3.23)(2.54)(2.09)(1.15)(2.55)
Weighted Avg Shares47.49M53.72M56.42M60.19M69.9M
Weighted Avg Shares (Diluted)47.49M54.08M56.42M60.19M69.9M

Health Catalyst, Inc.

NASDAQ:HCAT

Intrinsic Alpha fair value

Locked

Current Price

$1.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.